|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-2-23
|
|
pubmed:abstractText |
Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BignerDarell DDD,
pubmed-author:DesjardinsAnnickA,
pubmed-author:DowellJeannette MJM,
pubmed-author:FriedmanAllan HAH,
pubmed-author:FriedmanHenry SHS,
pubmed-author:GururanganSridharanS,
pubmed-author:HerndonJames EJE2nd,
pubmed-author:QuinnJennifer AJA,
pubmed-author:ReardonDavid ADA,
pubmed-author:RichJeremy NJN,
pubmed-author:SathornsumeteeSithS,
pubmed-author:VredenburghJames JJJ,
pubmed-author:WagnerMelissaM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1253-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17317837-Adult,
pubmed-meshheading:17317837-Aged,
pubmed-meshheading:17317837-Antibodies, Monoclonal,
pubmed-meshheading:17317837-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17317837-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17317837-Brain Neoplasms,
pubmed-meshheading:17317837-Camptothecin,
pubmed-meshheading:17317837-Female,
pubmed-meshheading:17317837-Glioma,
pubmed-meshheading:17317837-Humans,
pubmed-meshheading:17317837-Male,
pubmed-meshheading:17317837-Middle Aged,
pubmed-meshheading:17317837-Neoplasm Recurrence, Local,
pubmed-meshheading:17317837-Prospective Studies
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
|
|
pubmed:affiliation |
The Preston Robert Tisch Brain Tumor Center and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. vrede001@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
